300347 泰格医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,707,56014.06%6,832,8016,603,1207,384,0397,085,471
减:营业总成本3,348,89213.82%6,312,6455,610,0485,554,1255,156,544
    其中:营业成本2,687,04418.24%4,959,6064,361,1074,535,5114,277,008
               财务费用42,285-33.18%99,90238,067(108,324)(158,124)
               资产减值损失(3,599)-16.21%(38,961)1,255(29,725)(2,416)
公允价值变动收益(443,324)394.54%42,256(501,688)352,771535,857
投资收益(2,432)-101.04%433,816166,642338,175102,751
    其中:对联营企业和合营企业的投资收益21,662-86.98%198,50731,271105,18339,763
营业利润(78,649)-117.70%1,009,420664,4192,486,9412,582,399
利润总额(80,215)-118.12%1,003,215664,4622,488,5332,585,377
减:所得税费用105,25631.80%198,159216,630338,606313,652
净利润(185,471)-151.12%805,056447,8312,149,9272,271,725
减:非控股权益227,688-1,210.20%(82,834)42,688125,077265,173
股东净利润(413,160)-207.78%887,890405,1432,024,8502,006,552

市场价值指针
每股收益 (元) *-0.480-206.67%1.0400.4702.3402.320
每股派息 (元) *----0.1260.3000.5680.550
每股净资产 (元) *22.621-5.10%24.34223.89824.10222.447
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容